Nevertheless, as populations age all across the globe, constant pain brought on by chronic illnesses in the elderly will surely become a matter of public health and compassion. A 2008 study inquired on the efficacy of cannabinoids other than THC in pain management. Painkillers with cannabinoids proved to be well tolerated, with minimum side-effects, and a prospect for low long-term toxicity. Furthermore, a combination of cannabidiol and opioids is thought to be the breakthrough of the future in palliative care.
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act. This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.